Text Size

SYMBICORT® in the Treatment of COPD (SRP COPD)

This study has been completed.
Sponsor:
Information provided by:
AstraZeneca
ClinicalTrials.gov Identifier:
NCT00564499
First received: November 26, 2007
Last updated: January 27, 2011
Last verified: January 2011
History of Changes
  Purpose

A Scientific Research Program to evaluate the efficacy of SYMBICORT® 320/9μg in the treatment of COPD in real life environment by General Practitioners


Condition
COPD

Study Type: Observational
Study Design: Observational Model: Case-Crossover
Time Perspective: Prospective
Official Title: A Scientific Research Program to Evaluate the Efficacy of SYMBICORT® 320/9μg in the Treatment of COPD in Real Life Environment by General Practitioners

Further study details as provided by AstraZeneca:

Study Start Date: March 2006
Study Completion Date: May 2007
  Eligibility

Ages Eligible for Study:   18 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Sampling Method:   Non-Probability Sample
Study Population

patients

Criteria

Inclusion Criteria:

  • patients (m/f) with COPD (GOLD stadium III and IV)

Exclusion Criteria:

  • patients who recently quit smoking (<3months)
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00564499

Sponsors and Collaborators
AstraZeneca
Investigators
Principal Investigator: E Louis, PR Université Libre de Liège
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00564499     History of Changes
Other Study ID Numbers: SRP-RB-COPD-2005/1
Study First Received: November 26, 2007
Last Updated: January 27, 2011
Health Authority: Belgium: Federal Agency for Medicinal Products and Health Products

Keywords provided by AstraZeneca:
COPD
Symbicort
General Practitioners

Additional relevant MeSH terms:
Pulmonary Disease, Chronic Obstructive
Lung Diseases, Obstructive
Lung Diseases
Respiratory Tract Diseases
Symbicort
 Anti-Asthmatic Agents
Respiratory System Agents
Therapeutic Uses
Pharmacologic Actions

ClinicalTrials.gov processed this record on June 18, 2013